Watch Now: Dr. Christopher Janson: ASGCT Presentation on Myrtelle’s Phase 1/2 Gene Therapy Clinical Trial in Patients with Canavan Disease
Article Date
June 6, 2023
This article is featured on another website.
Go to article
June 27, 2023
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa. , June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck , Ph.D.
June 27, 2023
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa. , June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck , Ph.D.